» Articles » PMID: 24397844

Is Quantitative Real Time Polymerase Chain Reaction MCAM Transcript Assay Really Suitable for Prognostic and Predictive Management of Melanoma Patients?

Overview
Journal Br J Dermatol
Specialty Dermatology
Date 2014 Jan 9
PMID 24397844
Citations 3
Authors
Affiliations
Soon will be listed here.
Citing Articles

Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146.

Rapanotti M, Campione E, Spallone G, Orlandi A, Bernardini S, Bianchi L Cell Death Discov. 2017; 3:17005.

PMID: 28280601 PMC: 5337524. DOI: 10.1038/cddiscovery.2017.5.


The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis.

De Luca A, Carpanese D, Rapanotti M, Viguria T, Forgione M, Rotili D Oncotarget. 2017; 8(9):15520-15538.

PMID: 28107182 PMC: 5362503. DOI: 10.18632/oncotarget.14690.


Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma.

Rapanotti M, Viguria T, Costanza G, Ricozzi I, Pierantozzi A, Di Stefani A Arch Dermatol Res. 2014; 306(6):527-37.

PMID: 24902661 PMC: 4107285. DOI: 10.1007/s00403-014-1473-7.